Cardiac Mapping Market Analysis

Global Cardiac Mapping Market Overview

Cardiac Mapping Market Size was valued at USD 2.3 Billion in 2022. The cardiac mapping market industry is projected to grow from USD 2.51 Billion in 2023 to USD 4.954 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.90% during the forecast period (2023 - 2032). One of the key market driver anticipated to fuel the growth of the  cardiac mapping systems market during the forecast period is the ageing population, which is followed by rising rates of incidence and prevalence of heart ailments. Furthermore, improved diagnostic accuracy for heart illness due to technical developments in cardiac mapping systems is anticipated to drive adoption of cardiac mapping systems in the years to come, possibly driving the expansion of the  cardiac mapping systems market.  

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Cardiac Mapping Market Trends

• Rising number of cardiovascular diseases is driving the market growth

The likelihood of an increase in cardiovascular disorders and technological advancements in cardiac mapping diagnostics are two factors that are projected to support market revenue growth. According to the World Health Organisation (WHO), the primary cause of mortality worldwide is cardiovascular diseases (CVDs), which are estimated to kill 17.9 million people annually. Heart attacks and strokes are the cause of more than four out of every five CVD fatalities, and a third of these deaths occur in those under the age of 70. Around 2% of all deaths from cardiovascular disease are brought on by rheumatic heart disease worldwide.

A significant driver of the market for cardiac mapping's revenue development is the pattern of high-profile product introductions by major competitors in the sector. The market is currently going through a rapid phase of development and revolutionizing how illnesses are diagnosed. As an illustration, in January 2022, Abbott announced the availability of the EnSite X EP System with EnSite Omnipolar Technology (OT), a cutting-edge cardiac mapping system designed to improve the treatment of cardiac arrhythmias and recently given U.S. Food and Drug Administration approval. Both the U.S. and Europe now have access to the new platform.

In the foreseeable future, evolving technology will likely hasten market expansion. With the introduction of new technology, old therapeutic alternatives are being replaced with ones that offer quicker outcomes, more accuracy and efficacy, and cover arrhythmia. The newest technologies are presented with non-fluoroscopy catheter navigation and with less exposure to ionizing radiation (fluoroscopy). These factors are probably motivating hospital doctors to adopt new technologies so that they can provide patients better treatment options that are also financially viable. Thus, driving the cardiac mapping market revenue.

Cardiac Mapping Market Segment Insights

Cardiac Mapping Product Insights

The  cardiac mapping market segmentation, based on product includes Contact Cardiac Mapping Systems, Non-Contact Cardiac Mapping Systems. The contact cardiac mapping systems segment dominated the market. It provides 3D mapping and the ability to detect and locate ablation catheters precisely. Growing rates of obesity and cardiovascular illness in children and newborns, both caused by sedentary lifestyles, are the main drivers of this trend. Major players are also developing specialized ventricular tachycardia and supra-ventricular tachycardia, which is boosting the development of the non-contact mapping system segment.

Figure 1  Cardiac Mapping Market, by Product, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Cardiac Mapping End User Insights

The  cardiac mapping market segmentation, based on end user, includes Hospitals & Clinics, Diagnostic Centers and Others. The hospitals & clinics category generated the most income because these facilities are where most people who have arrhythmias are diagnosed and treated. The development of cardiac mapping technology and the quick growth of product makers' distribution networks for extensive contract cardiac mapping availability are other factors driving the market over the forecast period.

Cardiac Mapping Indication Insights

The  cardiac mapping market segmentation, based on indication, includes Atrial Fibrillation, Atrial Flutter, AVNRT And Others. The atrial fibrillation category generated the most income. Due to the sharp increase in the prevalence of cardiac mapping in industrialized countries, atrial fibrillation is a common arrhythmia that is used to characterize. The ability to pinpoint the precise sites of ablation and lure catheters in a 3D ecosystem, together with multi-electrode basket catheters that can reveal the arrhythmia circuit by recording just a few beats, are factors that are increasing the use of this technology.

Cardiac Mapping Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American cardiac mapping market area will dominate this market. This is a result of the high prevalence of CVDs, the rising acceptance rate of U.S. cardiac mapping systems, and clinical trials validating cardiac mapping systems, all of which are anticipated to spur demand growth throughout the anticipated timeframe in the market of North America. Additionally, the growing emphasis of government organisations on sponsoring research and the rise in the number of senior citizens in Canada all contribute to the region's development.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  CARDIAC MAPPING MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe cardiac mapping market accounts for the second-largest market share. This is mostly attributable to the vast patient population of cardiovascular illnesses. The German cardiac mapping market had the greatest revenue share in 2022. Nearly 40% of all fatalities in Germany are caused by cardiovascular diseases. They also have negative effects on people's health and result in high medical costs for society. Further, the German cardiac mapping market held the largest market share, and the UK cardiac mapping market was the fastest growing market in the European region

The Asia-Pacific Cardiac mapping Market is expected to grow at the fastest CAGR from 2023 to 2032 because there is a larger patient base for cardiovascular disorders and a growing demand for improved solutions to shorten wait times and increase diagnostic effectiveness. Moreover, China’s cardiac mapping market held the largest market share, and the Indian cardiac mapping market was the fastest growing market in the Asia-Pacific region.

Cardiac Mapping Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the cardiac mapping market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, cardiac mapping industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  cardiac mapping industry to benefit clients and increase the market sector. In recent years, the cardiac mapping industry has offered some of the most significant advantages to market. Major players in the cardiac mapping market attempting to increase market demand by investing in research and development operations include Abbott Laboratories, GE Healthcare, Boston Scientific Corporation, Medtronic plc., Johnson & Johnson, Koninklijke Philips N.V., Hill-Rom Services, Inc., and others.

Abbott Laboratories (Abbott) researches, develops, produces, and markets a wide array of healthcare goods, including branded generic medications, diagnostic tools, and infant, adolescent, and adult nutritional supplements. The company also offers a variety of medical devices for heart failure, vascular and structural issues with the heart, electrophysiology, rhythm regulation, neuromodulation, and more. Additionally, the business sells dietary supplements as well as minerals and nutrition goods.

Boston Scientific Corp. (Boston Scientific) is a manufacturer, developer, and marketer of medical technology products for a variety of interventional medical specialties. The business provides goods in the following specialties electrophysiology, gastroenterology, gastrointestinal surgery, female gynecology, interventional cardiology, interventional radiology, pelvic medicine, neurological surgery, orthopedic surgery, pain management, pulmonology, urology, and vascular surgery. Worldwide, Boston Scientific provides services to medical practices, clinics, outpatient facilities, and hospitals.

Key Companies in the cardiac mapping market include

• Abbott Laboratories


• GE Healthcare


• Boston Scientific Corporation


• Medtronic plc.


• Johnson & Johnson


• Koninklijke Philips N.V.


• Hill-Rom Services, Inc.

Cardiac Mapping Industry Developments

September 2022 The Octaray, a new mapping catheter from Johnson & Johnson MedTech subsidiary Biosense Webster, features eight splines and may make it easier for electrophysiologists to map cardiac arrhythmias. For the mapping of cardiac arrhythmias, including atrial fibrillation (AFib), a novel cardiac mapping catheter was created.

April 2022 The University Hospital in Basel, Switzerland, sponsored a clinical trial to describe the precise location of NOAF-maintaining foci and rotors after cardiac surgery that were found by mapping using low-dose computed tomography scans of the chest and noninvasive phase mapping with CardioInsightTM - 3D Mapping technology.

June 2021 In order to improve early detection and diagnosis of cardiac arrhythmias like atrial fibrillation (AFib), Cardiac Insight, Inc., a healthcare technology company with headquarters in the United States, focuses on wearable cardiac sensors and proprietary software that automatically analyses Electrocardiogram (ECG) data.

Cardiac Mapping Market Segmentation

Cardiac Mapping Product Outlook (USD Billion, 2018-2032)

• Contact Cardiac Mapping Systems


• Non-Contact Cardiac Mapping Systems

Cardiac Mapping End User Outlook (USD Billion, 2018-2032)

• Hospitals & Clinics


• Diagnostic Centers


• Others

Cardiac Mapping Indication  Outlook (USD Billion, 2018-2032)

• Atrial Fibrillation


• Atrial Flutter


• AVNRT


• Others

Cardiac Mapping Regional Outlook (USD Billion, 2018-2032)

• 
  North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America